文献速递垂体与肾上腺疾病

盐皮质激素受体拮抗剂对原发性醛固酮增多症患者醛固酮与肾素比值的影响

Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该前瞻性研究纳入121例确诊原发性醛固酮增多症并开始坎利酮治疗的患者,评估盐皮质激素受体拮抗剂对醛固酮与肾素比值的影响。结果显示,短期和长期治疗后肾素和钾显著升高,醛固酮与肾素比值显著降低,且假阴性率随治疗时间延长而升高。结论认为,在筛查原发性醛固酮增多症前应避免使用盐皮质激素受体拮抗剂。

要点

  • 坎利酮治疗可显著降低醛固酮与肾素比值,且效应随剂量和疗程增加。
  • 治疗2周、8周、2-6个月、7-12个月后假阴性率分别升至16.7%、38.9%、54.5%、72.5%。
  • 筛查原发性醛固酮增多症前应避免使用盐皮质激素受体拮抗剂。

核心结论

  • 盐皮质激素受体拮抗剂应避免在高血压患者进行肾素和醛固酮筛查原发性醛固酮增多症前使用。

研究设计与样本

  • 前瞻性研究纳入121例确诊原发性醛固酮增多症并开始坎利酮治疗的患者。
  • 长期队列102例(单侧16例,双侧67例,未定类型19例),在治疗2至12个月后复查激素和生化指标。

主要发现

  • 短期和长期治疗后,肾素和钾水平较基线显著升高,醛固酮与肾素比值显著降低。
  • 上述效应随坎利酮剂量增加和治疗时间延长而更明显。
  • 坎利酮对筛查试验诊断准确性有显著影响,假阴性率在治疗2周、8周、2至6个月、7至12个月后分别升至16.7%、38.9%、54.5%、72.5%。

临床怎么用

  • 在筛查原发性醛固酮增多症前,应避免使用盐皮质激素受体拮抗剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although current international guidelines recommend to avoid mineralocortcoid receptor antagonists in patients undergoing screening test for primary aldosteronism, a recent report suggested that mineralocorticoid receptor antagonist treatment can be continued without significant influence on screening results. OBJECTIVE: We aimed to evaluate the effect of mineralocorticoid receptor antagonists on the aldosterone to renin ratio in patients with primary aldosteronism. METHODS: We prospectively enrolled 121 patients with confirmed primary aldosteronism who started mineralocorticoid receptor antagonist (canrenone) treatment. Eighteen patients (11 with unilateral and 7 with bilateral primary aldosteronism) constituted the short-term study cohort and underwent aldosterone, renin, and potassium measurement after 2 and 8 weeks of canrenone therapy. The long-term cohort comprised 102 patients (16 with unilateral and 67 with bilateral primary aldosteronism, and 19 with undetermined subtype) who underwent hormonal and biochemical re-assessment after 2 to 12 months of canrenone therapy. RESULTS: Renin and potassium levels showed a significant increase, and the aldosterone to renin ratio displayed a significant reduction compared with baseline after both a short- and long-term treatment. These effects were progressively more evident with higher doses of canrenone and after longer periods of treatment. We demonstrated that canrenone exerted a deep impact on the diagnostic accuracy of the screening test for primary aldosteronism: the rate of false negative tests was raised to 16.7%, 38.9%, 54.5%, and 72.5% after 2 weeks, 8 weeks, 2 to 6 months, and 7 to 12 months of mineralocorticoid receptor antagonist treatment, respectively. CONCLUSION: Mineralocorticoid receptor antagonists should be avoided in patients with hypertension before measurement of renin and aldosterone for screening of primary aldosteronism.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Pecori A, Buffolo F, Burrello J, et al. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. J Clin Endocrinol Metab. 2021. PMID: 33942084. doi:10.1210/clinem/dgab290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。